GeneQiming Biotech Secures Over RMB 100 Million in New Financing and Files for IPO

Recently, Beijing Gene Key Life Technology Co., Ltd. announced the completion of a new round of financing exceeding 100 million yuan. This round of financing was led by Shenzhen Hua Xia Ren He Capital Management Co., Ltd. The proceeds will mainly be used to advance the company's clinical trials of iNKT cell drugs and the research and development of new pipelines.

Founded in 2015, Beijing Gene Key Life Technology Co., Ltd., located in the Zhongguan Village (Daxing) Cell and Gene Therapy Industrial Park, Daxing District, Beijing, is a national high-tech enterprise and the world's first leading company dedicated to the research and development of iNKT cell series therapeutic products. The company not only has a strong team specializing in fundamental biomedical and immunological research but also has established a complete technical platform system covering basic research, clinical transformation, and pilot production. Notably, it operates China’s largest iNKT cell pilot platform and an ultra-large-scale expansion and culture system.

iNKT Cells（invariant Natural Killer T cells) isA unique type of immune cell that combines the specific cytotoxic capabilities of T cells with the rapid response characteristics of NK cells. It does not rely on the traditional HLA molecule recognition mechanism, thus effectively avoiding the risk of graft-versus-host disease (GvHD). At the same time, it can overcome the immunosuppressive barrier in the solid tumor microenvironment, showing great potential in tumor immunotherapy.

▲ Compared with T cells and NK cells, iNKT cells have significant advantages.

As a key bridge connecting innate immunity and adaptive immunity, iNKT cells can rapidly secrete large amounts of cytokines and recognize lipid antigens presented by CD1d molecules, including specific molecules from pathogens, commensal bacteria, and even self-origin, demonstrating broad application prospects.

▲ Schematic diagram of iNKT cell immune effects

Relying on its fully independent intellectual property rights iNKT cell hyperexpansion platform and unique subpopulation distribution regulation technologies, Gene Key Life Technology has achieved high-quality, large-scale preparation of iNKT cells and made several "world-first" and "China-first" breakthroughs in this field: the world's first completion of safety and efficacy verification for iNKT cell therapy in primary liver cancer; its self-developed GKL-006 injection has successively received approval from the National Medical Products Administration to conduct clinical trials for unresectable primary hepatocellular carcinoma, postoperative high-risk recurrence prevention, and advanced pancreatic cancer. Additionally, the company has successfully developed China’s first allogeneic off-the-shelf iNKT cell injection (GKL-006Allo) and a novel ready-to-use product (GKL-006RTU), respectively for treating solid tumors after standard therapy failure and moderate to severe acute respiratory distress syndrome caused by infections, both of which have been approved.National Medical Products AdministrationClinical Trial Approval.

With a series of international inventionsPatents andSignificant Progress in Multiple Clinical StudiesGene Key Life Technology not only achieved a significant breakthrough in China's core technology of iNKT cell therapy but also promoted the upgrading and development of related industries, establishing China’s leading position globally in this field.Bring more to the vast number of patientsPromising innovative therapies.

Statement:ParticipateWithin ChinaSource: Beijing Gene Key Life Technology Co., Ltd., Shenzhen Hua Xia Ren He Capital Management Co., Ltd....etc., this official account platform aims at knowledge sharing, maintaining a neutral stance on the content, statements, and viewpoints of reprinted or shared materials, without guaranteeing their accuracy.Accuracy, reliability, or completeness cannot be guaranteed, either explicitly or implicitly, and the relevant content is for reference only.